The STAT4 gene influences the genetic predisposition to systemic sclerosis phenotype.
暂无分享,去创建一个
R. Scorza | N. Ortego-Centeno | J. V. van Laar | M. Vonk | G. Riemekasten | L. Beretta | J. Sánchez-Román | M. González-Escribano | T. Radstake | J. Nelson | B. Rueda | R. Hesselstrand | C. Simeón | N. Ortego-Centeno | M. Gonzalez-gay | M. Coenen | J. Martín | M. Camps | M. Aguirre-Zamorano | J. Broen | A. Pros | P. Airo | F. van den Hoogen | F. V. D. Hoogen | V. Fonollosa | R. García-Portales | B. Díaz | H. Suárez | F. V. D. van den Hoogen | P. Airò | J. Martin | J. M. V. Laar
[1] M. Gershwin,et al. The immunobiology of systemic sclerosis. , 2008, Seminars in arthritis and rheumatism.
[2] M. Zervou,et al. STAT4: a risk factor for type 1 diabetes? , 2008, Human immunology.
[3] E. G. de la Concha,et al. Association of the STAT4 gene with increased susceptibility for some immune-mediated diseases. , 2008, Arthritis and rheumatism.
[4] John P A Ioannidis,et al. Effect of formal statistical significance on the credibility of observational associations. , 2008, American journal of epidemiology.
[5] C. Wijmenga,et al. Association of STAT4 with rheumatoid arthritis: a replication study in three European populations. , 2008, Arthritis and rheumatism.
[6] J. Reveille,et al. The contribution of genes outside the major histocompatibility complex to susceptibility to ankylosing spondylitis , 2008, Current opinion in rheumatology.
[7] A. Syvänen,et al. A risk haplotype of STAT4 for systemic lupus erythematosus is over-expressed, correlates with anti-dsDNA and shows additive effects with two risk alleles of IRF5 , 2008, Human molecular genetics.
[8] Judy H. Cho,et al. The genetics and immunopathogenesis of inflammatory bowel disease , 2008, Nature Reviews Immunology.
[9] J. Anaya,et al. STAT4 but not TRAF1/C5 variants influence the risk of developing rheumatoid arthritis and systemic lupus erythematosus in Colombians , 2008, Genes and Immunity.
[10] F. Holsboer,et al. IL 2 RA and IL 7 RA genes confer susceptibility for multiple sclerosis in two independent European populations , 2008 .
[11] F. Arnett,et al. Genetics and genomic studies in scleroderma (systemic sclerosis). , 2008, Rheumatic diseases clinics of North America.
[12] M. Fujimoto,et al. Increased serum interleukin 23 in patients with systemic sclerosis. , 2008, The Journal of rheumatology.
[13] John P. A. Ioannidis,et al. Methods for meta-analysis in genetic association studies: a review of their potential and pitfalls , 2008, Human Genetics.
[14] D. Abraham,et al. Possible implication of the effector CD4+ T-cell subpopulation TH17 in the pathogenesis of systemic scleroderma , 2007, Nature Clinical Practice Rheumatology.
[15] Wentian Li,et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. , 2007, The New England journal of medicine.
[16] Z. Nagy,et al. Regulation of T cell homeostasis by JAKs and STATs , 2007, Archivum Immunologiae et Therapiae Experimentalis.
[17] D. G. Zisoulis,et al. Stat3 and Stat4 Direct Development of IL-17-Secreting Th Cells1 , 2007, The Journal of Immunology.
[18] P. Gregersen,et al. Genetics of autoimmune diseases — disorders of immune homeostasis , 2006, Nature Reviews Genetics.
[19] Xinmin Cao,et al. Structure, function, and regulation of STAT proteins. , 2006, Molecular bioSystems.
[20] P. Gregersen,et al. PTPN22: setting thresholds for autoimmunity. , 2006, Seminars in immunology.
[21] D. Abraham,et al. Mechanisms and consequences of fibrosis in systemic sclerosis , 2006, Nature Clinical Practice Rheumatology.
[22] T. Merriman,et al. Genetic progress towards the molecular basis of common autoimmunity. , 2006, Discovery medicine.
[23] Yuka Kanno,et al. Signaling by IL‐12 and IL‐23 and the immunoregulatory roles of STAT4 , 2004, Immunological reviews.
[24] U. Zettl,et al. Transcription factors in autoimmune diseases. , 2004, Current pharmaceutical design.
[25] S. Jimenez,et al. Following the Molecular Pathways toward an Understanding of the Pathogenesis of Systemic Sclerosis , 2004, Annals of Internal Medicine.
[26] C. Denton,et al. Assessment of lung involvement. , 2003, Clinical and experimental rheumatology.
[27] T. Medsger,et al. Criteria for the classification of early systemic sclerosis. , 2001, The Journal of rheumatology.
[28] M. Hasegawa,et al. Levels of interleukin 12, a cytokine of type 1 helper T cells, are elevated in sera from patients with systemic sclerosis. , 2000, The Journal of rheumatology.
[29] S. Baigent,et al. Elevated levels of corticotrophin-releasing factor binding protein in the blood of patients suffering from arthritis and septicaemia and the presence of novel ligands in synovial fluid. , 1996, British journal of rheumatology.
[30] T. Medsger,et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. , 1988, The Journal of rheumatology.
[31] A. Masi. Preliminary criteria for the classification of systemic sclerosis (scleroderma). , 1980, Bulletin on the rheumatic diseases.